Seaport Therapeutics, Inc.
USD · NASDAQ:SPTX
Issue Size
$254.88M
Price Range
$16.00 - $18.00
Shares
53.03M o/s · 14.16M offered
Listing Price
$21.00
Listing date
May 01, 2026
Sector
Healthcare
About
Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform.
The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects.
Seaport Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:SPTX
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Profitability & Returns
Margins and return on capital
Analyst Estimates
Street consensus and price targets
Risk Metrics
Volatility versus the market
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | $18.61 | $18.68 | $17.84 | $18.19 | $18.19 | -0.42 | 112,600 |
| 2026-05-28 | $17.88 | $19.30 | $17.88 | $18.80 | $18.80 | +0.92 | 316,700 |
| 2026-05-27 | $18.00 | $18.24 | $17.80 | $18.05 | $18.05 | +0.05 | 118,300 |
| 2026-05-26 | $17.72 | $18.25 | $17.32 | $18.01 | $18.01 | +0.29 | 181,100 |
| 2026-05-22 | $17.19 | $17.69 | $16.53 | $17.50 | $17.50 | +0.31 | 214,600 |
| 2026-05-21 | $16.00 | $17.52 | $15.67 | $17.19 | $17.19 | +1.19 | 209,900 |
| 2026-05-20 | $16.34 | $16.76 | $15.52 | $15.78 | $15.78 | -0.56 | 266,100 |
| 2026-05-19 | $15.67 | $16.26 | $15.01 | $15.66 | $15.66 | -0.01 | 158,900 |
| 2026-05-18 | $16.85 | $16.85 | $15.00 | $15.74 | $15.74 | -1.11 | 421,800 |
| 2026-05-15 | $16.77 | $17.23 | $16.19 | $16.81 | $16.81 | +0.04 | 611,600 |
| 2026-05-14 | $16.50 | $17.36 | $16.10 | $16.94 | $16.94 | +0.44 | 380,300 |
| 2026-05-13 | $16.10 | $16.70 | $15.57 | $16.50 | $16.50 | +0.40 | 431,700 |
| 2026-05-12 | $15.39 | $16.05 | $15.30 | $15.95 | $15.95 | +0.56 | 155,000 |
| 2026-05-11 | $16.00 | $16.44 | $14.94 | $15.25 | $15.25 | -0.75 | 399,500 |
| 2026-05-08 | $15.75 | $16.24 | $15.44 | $16.05 | $16.05 | +0.30 | 304,100 |
| 2026-05-07 | $16.05 | $16.08 | $14.85 | $15.50 | $15.50 | -0.55 | 429,700 |
| 2026-05-06 | $16.01 | $16.46 | $15.35 | $16.00 | $16.00 | -0.01 | 498,600 |
| 2026-05-05 | $17.35 | $17.86 | $15.21 | $16.00 | $16.00 | -1.35 | 892,700 |
| 2026-05-04 | $19.17 | $19.17 | $16.90 | $17.00 | $17.00 | -2.17 | 910,700 |
| 2026-05-01 | $21.00 | $23.00 | $19.50 | $19.84 | $19.84 | -1.16 | 4,697,700 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | May 11, 2026 | Filing |
| SCHEDULE 13G | May 11, 2026 | Filing |
| SCHEDULE 13D | May 6, 2026 | Filing |
| 8-K | May 4, 2026 | Current Report |
| S-8 | May 4, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | May 1, 2026 | Prospectus |
| EFFECT | Apr 30, 2026 | Notice of Effectiveness |
| S-1MEF | Apr 30, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Apr 30, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Apr 28, 2026 | Registration of securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Daphne Zohar
Chief Executive Officer and Director
Michael C. Chen, Ph.D.
Chief Scientific Officer
Lana Gladstein, J.D.
General Counsel
Antony Loebel, M.D.
Chief Medical Officer
Lauren A. White
Chief Financial Officer
Steven M. Paul, M.D.
Director and Board Chair
Eric Elenko, Ph.D.
Director
James I. Healy, M.D., Ph.D.
Director
Robert J. Hombach
Director
Robert Nelsen
Director
